# moderate-to-severe atopic dermatitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis

> 4 upcoming FDA catalysts in moderate-to-severe atopic dermatitis: rezpegaldesleukin (NKTR) on May 2028 (primary completion); rezpegaldesleukin (NKTR) on May to Aug 2028 (topline data readout); rezpegaldesleukin (NKTR) on June 2028 (primary completion); rezpegaldesleukin (NKTR) on Jun to Sep 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | moderate-to-severe atopic dermatitis | completed | "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial), which is ongoing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm)) |
| Apr 2024 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | moderate to severe atopic dermatitis | completed | "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm)) |
| 1H 2025 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | moderate-to-severe atopic dermatitis | scheduled | "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm)) |
| Q1 2025 | [Olevaprubart trial start](https://sec-api.dev/pdufa/olevaprubart) | HCM | moderate-to-severe atopic dermatitis | scheduled | "Initiation of a Phase IIb dose-finding study with IMG-007's subcutaneous formulation in patients with moderate-to-severe atopic dermatitis is planned for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000110465925025364/tm2423664d2_ex99-1.htm)) |
| Q2 2025 | [Bosakitug trial start](https://sec-api.dev/pdufa/bosakitug) | ACRS | moderate to severe atopic dermatitis | scheduled | "Aclaris Expects to Initiate Enrollment in Placebo-Controlled Two-Arm Phase 2 Trial in Atopic Dermatitis (AD) in the Second Quarter of 2025: Based on the potency of bosakitug observed in preclinical and clinical studies to date, including the compelling results of the Phase 2a single arm trial in AD, Aclaris intends to initiate a two-arm placebo-controlled Phase 2 trial of bosakitug in approximately 90 patients with moderate-" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508xex99d1.htm)) |
| May 6, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate to Severe Atopic Dermatitis | completed | "NCT06136741 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136741)) |
| Q3 2025 | [ABCL575 trial start](https://sec-api.dev/pdufa/abcl575) | ABCL | moderate-to-severe atopic dermatitis | scheduled | "AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 VANCOUVER, British Columbia- AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000162828025028529/a8k2025-05x30abclexhibit.htm)) |
| Q1 2026 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | moderate to severe atopic dermatitis | scheduled | "Based on these positive results, the Company plans to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm)) |
| Mar 2026 | [ARQ-234 trial start](https://sec-api.dev/pdufa/arq-234) | ARQT | moderate-to-severe atopic dermatitis | completed | "In March 2026, the Company initiated a Phase 1a/1b clinical trial of ARQ-234 for the treatment of moderate-to-severe atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000057/arqt-20260930.htm)) |
| May 2028 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07690371)) |
| May to Aug 2028 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07690371)) |
| June 2028 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07711418)) |
| Jun to Sep 2028 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07711418)) |

## Drugs

- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin) (NKTR)
- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib) (CRVS)
- [Olevaprubart](https://sec-api.dev/pdufa/olevaprubart) (IMA)
- [Bosakitug](https://sec-api.dev/pdufa/bosakitug) (ACRS)
- [ABCL575](https://sec-api.dev/pdufa/abcl575) (ABCL)
- [ARQ-234](https://sec-api.dev/pdufa/arq-234) (ARQT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate-to-severe atopic dermatitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis

```bibtex
@misc{secapidev_indications_moderate_to_severe_atopic_dermatitis_20261116,
  title        = {moderate-to-severe atopic dermatitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_atopic_dermatitis_20261116","title":"moderate-to-severe atopic dermatitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
